Den europeiske union - slovakisk - EMA (European Medicines Agency)

novo nordisk a/s - nonacog beta pegol - hemofília b - antihemoragiká - liečba a profylaxia krvácania u pacientov s hemofíliou b (vrodený nedostatok faktora ix). , refixia can be used for all age groups.

Den europeiske union - polsk - EMA (European Medicines Agency)

baxalta innovations gmbh - rurioktocog alfa pegol - hemofilia - antykrościeryczne - leczenie i profilaktyka krwawienia u pacjentów w wieku 12 lat i starszych z hemofilią a (wrodzony niedobór czynnika viii).

Den europeiske union - slovakisk - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemofília a - antihemoragiká - liečba a profylaxia krvácania u pacientov vo veku 12 rokov a starších s hemofíliou a (vrodená deficiencia faktora viii).

Den europeiske union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemophilia a - antihemorrhagics - behandling og profylakse af blødning hos patienter 12 år og derover med hæmofili a (medfødt faktor viii-mangel).

Den europeiske union - dansk - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohnsygdom - immunosuppressiva - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia kan gives som monoterapi i tilfælde af intolerance overfor methotrexat eller når fortsatte behandling med methotrexat er upassende. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemophilia a - antihemorragica - behandeling en profylaxe van bloedingen bij patiënten van 12 jaar en ouder met hemofilie a (aangeboren factor-viii-tekort).

Den europeiske union - ungarsk - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemofília a - antihaemorrhagiás - a vérzés kezelésére és megelőzésére 12 éves vagy annál idősebb betegeknél az a hemofília (veleszületett viii-as faktor hiány).

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - ziekte van crohn - immunosuppressiva - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia kan worden gegeven als monotherapie in geval van intolerantie voor methotrexaat of wanneer voortgezette behandeling met methotrexaat als ongepast. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Den europeiske union - dansk - EMA (European Medicines Agency)

baxalta innovations gmbh - rurioctocog alfa pegol - hemophilia a - antihemorrhagics - behandling og profylakse af blødning hos patienter 12 år og derover med hæmofili a (medfødt faktor viii-mangel).

Den europeiske union - dansk - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemophilia a - antihemorrhagics - behandling og profylakse af blødning hos tidligere behandlede patienter ≥ 12 år med hæmofili a (medfødt faktor viii-mangel).